STOCK TITAN

BioNexus Gene Lab (BGLC) Stock Price, News & Analysis

BGLC NASDAQ
Published by Stock Titan Data refreshed

What Changed

Price Move History

Daily moves over 5%
58 249 sessions, November 17, 2025 to November 17, 2026
Largest daily move
+16.8% close of June 15, 2026
1-year change
-83.6% closing prices, November 17, 2025 to November 17, 2026
1-month change
-36.2% closing prices, October 16, 2026 to November 17, 2026

Company Description

BioNexus Gene Lab Corp (Nasdaq: BGLC) is a Wyoming-incorporated biotechnology company headquartered in Kuala Lumpur, Malaysia. According to company disclosures and press releases, BioNexus focuses on precision diagnostics, gene-based technologies, and biologics, with an emphasis on oncology and advanced molecular testing across Southeast Asia and selected international markets.

The company describes itself as a precision diagnostics company focused on Southeast Asia, operating laboratories and partnerships across the region. Through these operations, BioNexus is building a portfolio of advanced molecular and AI-enabled tests intended to make next-generation oncology diagnostics more accessible and actionable. Its activities include the development and provision of non-invasive liquid biopsy tests and RNA-based genomic diagnostics that analyze changes in RNA to detect potential risk of different diseases.

Business Focus and Operating Divisions

BioNexus Gene Lab Corp reports that it is advancing a multi-pronged strategy that combines healthcare diagnostics and specialty materials. Through its subsidiaries MRNA Scientific Sdn. Bhd. and Chemrex Corporation Sdn. Bhd., the company is involved in:

  • Oncology and genomic diagnostics via MRNA Scientific, including non-invasive blood tests that screen for multiple diseases and molecular screening platforms.
  • Specialty chemical raw materials distribution through Chemrex, which serves industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in Southeast Asia.

Company communications describe this as a diversified biotechnology and specialty materials group, combining precision medical diagnostics with high-performance chemical raw materials and biologics-related manufacturing capabilities.

Precision Oncology and Liquid Biopsy Platforms

A core strategic theme for BioNexus is the expansion of precision oncology in Southeast Asia. The company has entered into a series of agreements and term sheets with Fidelion Diagnostics Pte. Ltd. and Tongshu Biotechnology relating to VitaGuard™, a tumor-naïve minimal residual disease (MRD) liquid biopsy platform based on circulating tumor DNA (ctDNA).

According to multiple press releases, BioNexus has:

  • Executed a Share Subscription and Shareholders’ Agreement with Fidelion and other parties, under which BioNexus agreed to subscribe for newly issued Fidelion shares so that it will hold at least 15% of Fidelion’s enlarged share capital at completion, in exchange for issuing restricted BioNexus shares.
  • Completed a strategic investment in Fidelion Diagnostics, resulting in a 15% equity stake in Fidelion and cross-shareholdings between the companies.
  • Secured exclusive, perpetual commercial rights to manufacture, market, and distribute VitaGuard-based MRD tests across Southeast Asia (ASEAN), including Malaysia, Singapore, Indonesia, and Thailand, under an exclusive intellectual property license agreement.

The company characterizes VitaGuard as a next-generation, AI-enabled MRD monitoring platform designed as a high-efficiency, high-fidelity liquid biopsy system. The licensed package includes core patents, proprietary protocols and standard operating procedures, and software for MRD analysis and report generation. BioNexus positions this platform as a foundation for a recurring-revenue oncology diagnostics franchise in an underpenetrated regional market.

In addition to diagnostics, BioNexus states that it is expanding into contract development and manufacturing organization (CDMO) services. Company communications describe plans to participate in biologics production, assay manufacturing, and diagnostic supply chains, with investments in quality systems, manufacturing capacity, and technical capabilities aligned with global CDMO standards.

Through its subsidiaries, the company aims to support biologics development, specialty manufacturing, and integrated laboratory services across Southeast Asia. This CDMO transformation is presented as a complement to its diagnostics activities, creating a broader biotechnology platform.

Specialty Materials and Chemical Raw Materials

BioNexus Gene Lab Corp also reports a business line focused on specialty materials via Chemrex Corporation Sdn. Bhd. Historical and current descriptions indicate that this subsidiary is involved in the sale of chemical raw materials for manufacturing in industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region, including Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia.

The company has indicated an intention to scale this specialty materials business into new areas of sustainable development and growth in upstream and downstream production, positioning it alongside healthcare diagnostics as part of a broader group structure.

Geographic Focus and Market Positioning

BioNexus highlights Southeast Asia as its primary geographic focus for diagnostics and therapeutics, citing a large and growing cancer burden and relatively limited access to advanced molecular diagnostics in the region. It describes plans to build a top-tier laboratory network and to lead regulatory submissions and commercialization efforts in markets such as Malaysia and Singapore, with broader ASEAN expansion contemplated.

The company also references activities and strategic aspirations in Asia and the U.S., including capital markets access through its Nasdaq listing and alignment with evolving digital infrastructure standards in the United States and Wyoming.

Therapeutic and Regenerative Medicine Initiatives

BioNexus has disclosed a non-binding Strategic Partnership Term Sheet with BirchBioMed Inc., a Canadian biopharmaceutical company. Under this framework, BioNexus would lead a financing round and collaborate on the commercialization of FS2 (kynurenic acid) topical platform in Southeast Asia. FS2 is described as a topical therapeutic candidate targeting fibrosis, hypertrophic scarring, and skin regeneration.

The contemplated collaboration includes strategic equity investment, market intelligence, regulatory and clinical-trial strategy guidance, and assistance in securing licensees and commercialization partners in Malaysia and Singapore. The company presents this as part of a growing portfolio in regenerative medicine and precision therapeutics. The term sheet is explicitly non-binding except for certain provisions, and there is no assurance that a definitive agreement will be executed.

Digital Assets and Ethereum Treasury Strategy

In its annual report and subsequent press releases, BioNexus describes a blockchain-native treasury strategy that prioritizes Ethereum (ETH) as a core strategic reserve asset. The company states that it approved this approach as part of a broader initiative to integrate blockchain technologies into its financial operations.

BioNexus has also announced a partnership with ML Tech, an AI-driven wealth management platform for digital assets, to optimize its Ethereum-based growth strategies. Under this collaboration, ML Tech provides quantitative trading strategies and infrastructure designed to grow BioNexus’s Ethereum holdings while maintaining risk management protocols. The company characterizes this as aligned with its focus on innovation in the digital and healthcare space.

Capital Markets and Financing Framework

BioNexus Gene Lab Corp is listed on The Nasdaq Stock Market LLC under the symbol BGLC. Company filings and press releases describe several capital markets initiatives, including:

  • A registration statement on Form S-3 to register up to $100 million of securities that may be offered from time to time.
  • An Equity Distribution Agreement with Maxim Group LLC, establishing an at-the-market (ATM) program for up to $20 million of common stock, subject to effectiveness of the shelf registration.
  • A $500 million Equity Purchase Agreement with ARC Group International Ltd., providing discretionary access to equity capital over a defined commitment period, with restrictions on ARC’s ownership level and trading activities.

The company indicates that these facilities are intended to provide financial flexibility to support diagnostics commercialization, CDMO expansion, and therapeutic development and commercialization programs. It has also reported regaining compliance with Nasdaq’s minimum bid price requirement following a reverse stock split and other measures.

Corporate Governance and Reporting

BioNexus has reported steps to strengthen corporate governance and internal controls, including the appointment of a new Chief Financial Officer and the formation of governance and audit functions. It has filed periodic reports with the U.S. Securities and Exchange Commission, including an annual report on Form 10-K that discusses strategic realignment, technological initiatives, and capital management.

The company has also filed notifications of late filing (Form 12b-25) when additional time was required to complete quarterly reporting, citing transitions in financial leadership. These disclosures indicate an intention to comply with U.S. securities law reporting requirements and Nasdaq rules.

Company Status

Based on the most recent SEC filings and Nasdaq references, BioNexus Gene Lab Corp remains a public company with common stock registered under Section 12(b) of the Securities Exchange Act of 1934 and listed on The Nasdaq Stock Market under the symbol BGLC. There is no indication in the provided filings or news of delisting, deregistration, completed merger, or bankruptcy.

Key Themes for Investors and Observers

From the available information, several recurring themes characterize BioNexus Gene Lab Corp:

  • A focus on precision oncology diagnostics, particularly liquid biopsy and MRD testing, with a regional emphasis on Southeast Asia.
  • Expansion into CDMO services, biologics development, and specialty manufacturing.
  • Continuation of a specialty chemical raw materials business serving multiple industrial sectors in Southeast Asia.
  • Strategic use of blockchain and digital assets within its treasury and financial operations.
  • Use of equity-based financing facilities and cross-equity partnerships to support growth initiatives.

All of these elements are drawn from the company’s own press releases and SEC filings, which provide the primary source of information about BioNexus Gene Lab Corp’s business model and strategic direction.

Stock Performance

$0.7600
-0.81%
-0.0062
Pre-marketLast updated: at
-83.6%
Performance 1 year

BioNexus Gene Lab (BGLC) closed at $0.7662 on November 17, 2026. Over the past 12 months, the price has lost 83.6%.

See what a $1,000 investment in BGLC would be worth today

Average down calculator for BGLC

BGLC Metrics & Rankings

Price returns through November 17, 2026. Month and year figures include the first trading day. Ranking links may use different dates.

Latest News

BioNexus Gene Lab has 10 recent news articles. Of the recent coverage, 5 articles coincided with positive price movement and 5 with negative movement. Key topics include AI, management. View all BGLC news →

Financial Highlights

BioNexus Gene Lab generated $7.4M in revenue in FY2025, retaining a 14.6% gross margin, operating income reached -$3.0M (-39.9% operating margin), and net income was -$3.0M, reflecting a -40.2% net profit margin. The company generated -$1.8M in operating cash flow. The current ratio was 10.46, measuring current assets divided by current liabilities.

$7.4M
Revenue (FY2025)
-$3.0M
Net Income (FY2025)
-$1.8M
Operating Cash Flow

Upcoming Events

MAR
31
March 31, 2027 Corporate

License closing deadline

Contract may be terminated if closing has not occurred by this date; closing remains subject to technology acceptance, diligence, approvals.
MAR
31
March 31, 2027 Corporate

Closing deadline

Either non-defaulting party may terminate the licence agreement if closing has not occurred by Mar 31, 2027, unless extended.

BioNexus Gene Lab has 2 upcoming scheduled events. The next event, "License closing deadline", is scheduled for March 31, 2027 (in 133 days). Investors can track these dates to stay informed about potential catalysts that may affect the BGLC stock price.

Short Interest History

Last 12 Months

Short interest in BioNexus Gene Lab (BGLC) currently stands at 3.2 thousand shares, down 64.9% from the previous reporting period, representing 0.2% of the float. Since November 2025, short interest has decreased by 90.9%.

Days to Cover History

Last 12 Months

Days to cover for BioNexus Gene Lab (BGLC) currently stands at 1.0 days. The ratio is the reported short interest divided by the average daily trading volume. Since November 2025, the figure has decreased by 64.5%. Across the settlements charted above, it has ranged from 1.0 to 4.5 days.

BGLC Company Profile & Sector Positioning

BioNexus Gene Lab (BGLC) operates in the Specialty Chemicals industry within the broader Basic Materials sector and is listed on the NASDAQ.

Investors comparing BGLC often look at related companies in the same sector, including CN Energy Group Inc. (CNEY), J-Star Holding Co., Ltd. (YMAT), SenesTech, Inc. (SNES), Bon Natural Life Limited (BON), and Loop Industries, Inc. (LOOP). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate BGLC's relative position within its industry.

Frequently Asked Questions

The current stock price of BioNexus Gene Lab (BGLC) is $0.7600 in pre-market trading as of November 18, 2026.

The market cap of BioNexus Gene Lab (BGLC) is approximately $2.2M. Learn more about what market capitalization means .

The FY2025 revenue of BioNexus Gene Lab (BGLC) is $7.4M, from its most recent completed fiscal year.

The FY2025 net income of BioNexus Gene Lab (BGLC) is -$3.0M, from its most recent completed fiscal year.

The operating cash flow of BioNexus Gene Lab (BGLC) is -$1.8M for FY2025, its most recent completed fiscal year. Learn about cash flow.

The net profit margin of BioNexus Gene Lab (BGLC) is -40.2% for FY2025, its most recent completed fiscal year. Learn about profit margins.

The operating profit margin of BioNexus Gene Lab (BGLC) is -39.9% for FY2025, its most recent completed fiscal year. Learn about operating margins.

The gross profit margin of BioNexus Gene Lab (BGLC) is 14.6% for FY2025, its most recent completed fiscal year. Learn about gross margins.

The current ratio of BioNexus Gene Lab (BGLC), current assets divided by current liabilities, was 10.46 at the end of FY2025, its most recent completed fiscal year. Learn about liquidity ratios.

The gross profit of BioNexus Gene Lab (BGLC) is $1.1M for FY2025, its most recent completed fiscal year.

The operating income of BioNexus Gene Lab (BGLC) is -$3.0M for FY2025, its most recent completed fiscal year. Learn about operating income.

BioNexus Gene Lab Corp is a Wyoming-incorporated biotechnology company headquartered in Kuala Lumpur, Malaysia. According to its press releases and SEC filings, the company focuses on precision diagnostics, gene-based technologies, biologics, and specialty materials. It operates laboratory and diagnostic businesses in oncology and genomics, and also distributes specialty chemical raw materials for various industrial sectors in Southeast Asia.

Company communications describe BioNexus as a precision diagnostics company focused on Southeast Asia, building a portfolio of advanced molecular and AI-enabled tests. A major emphasis is on oncology diagnostics, including non-invasive liquid biopsy tests and RNA-based genomic diagnostics that analyze changes in RNA to detect potential disease risk.

VitaGuard™ is described as a next-generation, tumor-naïve minimal residual disease (MRD) liquid biopsy platform based on circulating tumor DNA (ctDNA). BioNexus has entered into definitive agreements and subsequent transactions with Fidelion Diagnostics and Tongshu Biotechnology under which it acquired a 15% equity stake in Fidelion and secured exclusive, perpetual rights to manufacture, market, and distribute VitaGuard-based tests across Southeast Asia.

BioNexus states that it is transforming its business to include contract development and manufacturing organization (CDMO) services. This expansion aims to support biologics production, assay manufacturing, and high-performance diagnostic supply chains. The company indicates that capital facilities such as an equity purchase agreement with ARC Group International are intended in part to fund quality-systems upgrades, manufacturing capacity, and technical capabilities aligned with global CDMO standards.

Chemrex Corporation Sdn. Bhd. is identified as a subsidiary of BioNexus involved in specialty materials. Historical and current descriptions indicate that Chemrex focuses on the sale of chemical raw materials for manufacturing in industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in Southeast Asia. The company has indicated plans to scale this business into new areas of sustainable development and production.

BioNexus is headquartered in Kuala Lumpur, Malaysia, and describes itself as a precision diagnostics company focused on Southeast Asia. It reports laboratories and partnerships across the region and highlights markets such as Malaysia, Singapore, Indonesia, and Thailand in connection with its exclusive rights to commercialize the VitaGuard MRD platform. Company materials also reference broader activities across Asia and the U.S.

In its annual report and subsequent announcements, BioNexus states that it approved a blockchain-native treasury strategy that prioritizes Ethereum (ETH) as a core strategic reserve asset. The company has partnered with ML Tech, an AI-driven digital asset platform, to apply quantitative trading strategies to its Ethereum holdings. This approach is presented as part of its broader focus on integrating blockchain technologies into financial operations.

BioNexus has disclosed several capital markets arrangements, including a shelf registration statement on Form S-3 for up to $100 million of securities, an Equity Distribution Agreement with Maxim Group LLC for a $20 million at-the-market program, and a $500 million Equity Purchase Agreement with ARC Group International Ltd. The company indicates that these facilities are intended to provide discretionary access to capital to support diagnostics commercialization, CDMO expansion, and therapeutic development and commercialization programs.

Yes. The company’s SEC filings list its common stock, no par value, as registered on The Nasdaq Stock Market LLC under the trading symbol BGLC. A press release dated April 30, 2025, states that BioNexus received notification from Nasdaq confirming that it had regained full compliance with the Nasdaq minimum bid price rule, and later filings continue to reference Nasdaq listing.

BioNexus has announced a non-binding Strategic Partnership Term Sheet with BirchBioMed Inc., a Canadian biopharmaceutical company. Under this framework, BioNexus would lead Birch’s financing round through a strategic equity investment and collaborate on the commercialization of Birch’s FS2 topical platform in Southeast Asia. The term sheet contemplates BioNexus providing market intelligence, regulatory and clinical-trial strategy guidance, and assistance in securing licensees and commercialization partners in Malaysia and Singapore, but it is explicitly non-binding except for certain provisions, and there is no assurance that a definitive agreement will be completed.